ATE537178T1 - Neue klasse von spiro-piperidinen zur behandlung neurodegenerativer krankheiten - Google Patents

Neue klasse von spiro-piperidinen zur behandlung neurodegenerativer krankheiten

Info

Publication number
ATE537178T1
ATE537178T1 AT09742523T AT09742523T ATE537178T1 AT E537178 T1 ATE537178 T1 AT E537178T1 AT 09742523 T AT09742523 T AT 09742523T AT 09742523 T AT09742523 T AT 09742523T AT E537178 T1 ATE537178 T1 AT E537178T1
Authority
AT
Austria
Prior art keywords
piperidines
spiro
treatment
neurodegenerative diseases
new class
Prior art date
Application number
AT09742523T
Other languages
English (en)
Inventor
Michael Brodney
Christopher HELAL
Brian O'neill
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE537178T1 publication Critical patent/ATE537178T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT09742523T 2008-05-05 2009-05-04 Neue klasse von spiro-piperidinen zur behandlung neurodegenerativer krankheiten ATE537178T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5042308P 2008-05-05 2008-05-05
PCT/IB2009/051815 WO2009136350A1 (en) 2008-05-05 2009-05-04 Novel class of spiro piperidines for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
ATE537178T1 true ATE537178T1 (de) 2011-12-15

Family

ID=40902870

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09742523T ATE537178T1 (de) 2008-05-05 2009-05-04 Neue klasse von spiro-piperidinen zur behandlung neurodegenerativer krankheiten

Country Status (22)

Country Link
US (1) US20110046160A1 (de)
EP (1) EP2300484B1 (de)
JP (1) JP2011519913A (de)
KR (1) KR20110000749A (de)
CN (1) CN102083841A (de)
AP (1) AP2010005456A0 (de)
AT (1) ATE537178T1 (de)
AU (1) AU2009245322B2 (de)
BR (1) BRPI0912433A2 (de)
CA (1) CA2721786A1 (de)
CO (1) CO6321280A2 (de)
CR (1) CR11759A (de)
DO (1) DOP2010000317A (de)
EA (1) EA201001566A1 (de)
EC (1) ECSP10010597A (de)
ES (1) ES2375913T3 (de)
IL (1) IL208793A0 (de)
MA (1) MA32290B1 (de)
MX (1) MX2010012066A (de)
NZ (1) NZ588589A (de)
SV (1) SV2010003725A (de)
WO (1) WO2009136350A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011125006A2 (en) * 2010-04-09 2011-10-13 Pfizer Inc. Novel sultam compounds
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
KR20140054295A (ko) 2011-08-22 2014-05-08 머크 샤프 앤드 돔 코포레이션 Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도
EP3233077B1 (de) 2014-12-19 2026-05-06 The Broad Institute, Inc. Dopamin-d2-rezeptor-liganden
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0418375A (pt) * 2004-01-08 2007-05-22 Hoffmann La Roche derivados de diaza-espiropiperidina
JP2006044497A (ja) * 2004-08-05 2006-02-16 Toyota Motor Corp 車輪情報処理装置
CA2583342A1 (en) * 2004-10-13 2006-04-27 Merck And Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer's disease
US8211904B2 (en) * 2005-07-18 2012-07-03 Merck, Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
AU2007293416A1 (en) * 2006-09-07 2008-03-13 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
AU2007342368A1 (en) * 2007-01-04 2008-07-17 Merck & Co., Inc. Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
JP2011519913A (ja) 2011-07-14
KR20110000749A (ko) 2011-01-05
SV2010003725A (es) 2011-07-05
CA2721786A1 (en) 2009-11-12
MA32290B1 (fr) 2011-05-02
ECSP10010597A (es) 2010-12-30
US20110046160A1 (en) 2011-02-24
CO6321280A2 (es) 2011-09-20
CR11759A (es) 2010-11-22
AU2009245322B2 (en) 2011-07-14
AP2010005456A0 (en) 2010-12-31
WO2009136350A1 (en) 2009-11-12
CN102083841A (zh) 2011-06-01
AU2009245322A1 (en) 2009-11-12
EP2300484A1 (de) 2011-03-30
EP2300484B1 (de) 2011-12-14
IL208793A0 (en) 2010-12-30
NZ588589A (en) 2012-07-27
BRPI0912433A2 (pt) 2015-12-22
EA201001566A1 (ru) 2011-04-29
DOP2010000317A (es) 2010-11-15
MX2010012066A (es) 2010-12-06
ES2375913T3 (es) 2012-03-07

Similar Documents

Publication Publication Date Title
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ATE399155T1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
EP2182983A4 (de) Behandlung von amyloidogenen erkrankungen
DE202012013074U8 (de) Zusammensetzungen zur Behandlung von HCV
EP2111223A4 (de) Aminderivatverbindungen zur behandlung von augenerkrankungen und -leiden
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
EP2135858A4 (de) Zusammensetzung zur behandlung von infektionserkrankungen
EP3871639C0 (de) Vorrichtung zur behandlung von gastroösophagealer refluxkrankheit
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
EP2141989A4 (de) Zusammensetzungen und verfahren zur vorbeugung und behandlung von suchtkrankheiten
EP2470553C0 (de) Polyhydroylierte gallensäure zur behandlung von gallenerkrankungen
EP3639853C0 (de) Verwendung von semaphorin-4d-bindenden molekülen zur behandlung neurodegenerativer erkrankungen
EP2579936A4 (de) Magensonde zur behandlung von adipositas
GB0910003D0 (en) Novel compounds for the treatment of neurodegenerative diseases
EP2217259A4 (de) Verfahren zur behandlung von erkrankungen mit mangel an thiolhaltiger verbindung
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
EP3769718C0 (de) Vorrichtung zur behandlung von darmerkrankungen
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
EP2718255A4 (de) Chinonverbindungen zur behandlung ape1-vermittelter krankheiten
EP2249765A4 (de) Dapson zur behandlung von rosascea
EP2437603A4 (de) Verfahren zur behandlung von hepatischer enzephalopathie
EP2767282A4 (de) Verwendung von glutarylhistamin zur behandlung von atemwegsinfektionen
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme